The Critical Role Of Core Breast Biopsy Needles in Molecular Subtyping Of Breast Cancer

https://www.mayoclinic.org/tests-procedures/breast-biopsy/about/pac-20384812

Abstract:

Modern breast cancer management has entered the era of molecular subtyping. This article focuses on the irreplaceable role of core breast biopsy needles in acquiring high-quality tissue samples. It elaborates on how these devices provide sufficient, intact tissue cores to support immunohistochemical testing and gene sequencing, thereby accurately identifying key biomarkers such as ER, PR, HER2, and Ki-67. This capability lays a solid foundation for formulating targeted therapy, endocrine therapy, and chemotherapy regimens.

Main Text:

Within the diagnostic and therapeutic chain of breast cancer, "precision diagnosis" is the only bridge to "precision treatment." The first cornerstone of this bridge is a high-quality tissue sample. The core breast biopsy needle is the central instrument for obtaining this sample. It is no longer merely a tool to distinguish "benign" from "malignant"; it is the key to unlocking the biological code of the tumor and guiding individualized treatment plans.

From Morphology to Molecular Profiling: The Ascending Value of Biopsy Samples

Traditional Fine Needle Aspiration Cytology (FNAC) can only acquire a limited number of cells. While helpful for determining malignancy, it fails to preserve tissue architectural information and struggles to meet the demands of complex downstream molecular testing. In contrast, the core breast biopsy needle excises a complete cylindrical tissue core, approximately 1–2 mm in diameter and several centimeters in length. This tissue core retains intact glandular structures and stromal components. More importantly, it provides a sufficient quantity of cells to support a series of critical molecular pathology assays.

Four Biomarkers Driving Precision Therapy

For confirmed invasive breast cancer, pathologists utilize formalin-fixed paraffin-embedded (FFPE) blocks derived from core biopsies to perform immunohistochemical (IHC) staining, evaluating four vital biomarkers:

1. Estrogen Receptor (ER) and Progesterone Receptor (PR):​ These are the core indicators determining whether a patient will benefit from endocrine therapy (e.g., tamoxifen, aromatase inhibitors). Positive expression implies that tumor growth depends on hormonal signaling; blocking these signals effectively inhibits the tumor. The ample sample volume provided by core biopsies ensures the reliability of these interpretations.
2. Human Epidermal Growth Factor Receptor 2 (HER2):​ HER2-positive breast cancer is an aggressive subtype for which specific targeted drugs (e.g., trastuzumab, pertuzumab) are available. Core biopsy samples allow for initial IHC screening and, when results are equivocal, enable direct utilization of the same tissue block for Fluorescence In SituHybridization (FISH) testing to precisely determine HER2 gene amplification status.
3. Proliferation Index Ki-67:​ This metric reflects the proliferative activity of tumor cells. The level of Ki-67 is a crucial basis for differentiating Luminal A from Luminal B subtypes, directly influencing decisions regarding the necessity and intensity of chemotherapy. The large sample size of core biopsies allows for a more accurate reflection of the tumor's overall proliferation level, avoiding sampling errors caused by insufficient tissue.

Toward a Broader Future: Genomics and the Complementarity of Liquid Biopsy

Beyond the aforementioned routine markers, tissue obtained via core breast biopsy needles serves as ideal material for high-throughput gene sequencing. Through whole-exome or targeted sequencing of tumor tissue, driver mutations such as PIK3CAor BRCA1/2can be identified, providing evidence for the use of novel targeted agents (e.g., PI3K inhibitors, PARP inhibitors). Furthermore, while circulating tumor DNA (ctDNA) liquid biopsy is rapidly evolving-primarily for monitoring recurrence and resistance-core biopsy tissue remains the undisputed "gold standard" for comprehensive and reliable genomic analysis at the time of initial diagnosis.

Conclusion

The value of the core breast biopsy needle has long transcended the scope of mere "sampling." It is the central hub connecting clinical imaging findings to molecular pathology decisions. Every precise puncture contributes to drawing a unique "molecular portrait" of the patient's tumor. The clearer this portrait, the more precisely physicians can select the most effective treatment regimen, avoiding ineffective or excessive therapy. This truly facilitates the transition from "one-size-fits-all" to "personalized medicine." It can be stated unequivocally: without high-quality biopsy tissue, there is no true precision medicine.